Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30338869 | 1.00 | RIPK1 (0.42) | RIPK1KDM4EPOLBTDP1MAPT | |
| SCHEMBL25817349 | 0.88 | RIPK1 (0.39) | RIPK1KDM4EMAPTUSP2TP53 | |
| SCHEMBL30338552 | 0.88 | RIPK1 (0.39) | RIPK1KDM4EMAPTUSP2TP53 | |
| SCHEMBL25301419 | 0.86 | RIPK1 (0.41) | RIPK1KDM4EPOLBMAPT | |
| SCHEMBL30338709 | 0.86 | RIPK1 (0.41) | RIPK1KDM4EPOLBMAPT | |
| SCHEMBL30338981 | 0.84 | RIPK1 (0.42) | RIPK1KDM4EPOLB | |
| SCHEMBL25255422 | 0.84 | RIPK1 (0.42) | RIPK1KDM4EPOLB | |
| SCHEMBL31205790 | 0.80 | RIPK1 (0.42) | RIPK1KDM4EPOLB | |
| SCHEMBL31205828 | 0.77 | RIPK1 (0.41) | RIPK1KDM4EMAPT | |
| SCHEMBL30338534 | 0.76 | RIPK1 (0.37) | RIPK1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | RIPK1 1/4885KDM4E 2270/4885POLB 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.